|Description||Duvelisib, also known as IPI-145 and INK-1197, is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, PI3K delta/gamma inhibitor IPI 145 prevents the activation of the PI3K delta/gamma-mediated signaling pathways which may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and inflammatory and autoimmune diseases. By selectively targeting these PI3K isoforms, PI3K signaling in normal, non-neoplastic cells is minimally or not affected which would result in a more favorable side effect profile.|
|B0084-462545||100 mg||$228||In stock|
|Appearance||white solid powder|
|Synonyms||IPI145; IPI 145; IPI-145. INK-1197; INK 1197; INK1197; Duvelisib.|
|Application||For research used only|
|Current Developer||Infinity Pharmaceuticals, Inc. and Intellikine|
GDC-0941 is a potent pan inhibitor of class I catalytic subunits of PI3K that inhibits p110α, β, δ, and γ with IC50 values of 3, 33, 3, and 75 nM.
AS605240 is a selective PI3Kgamma inhibitor, has been proved effective on several inflammatory diseases. Orally administration of AS605240 significantly prevent...
ETP 45658 is a PI 3-kinase inhibitor (IC50 = 22, 30, 129 and 710 nM for PI 3-Kα, PI 3-Kδ, PI 3-Kβ and PI 3-Kγ, respectively), and it also inhibits DNA-PK and mT...
IC-87114 is a potent and selective PI3Kδ inhibitor with IC50 of 0.5 μM.
AZD-8835 was selected as a clinical candidate for the treatment of PIK3CA-dependent cancers and is currently in phase I clinical trials. It is an orally bioavai...
XL 765 is a PI3K inhibitor used for the treatment of cancers. It also suppresses DNA-PK and mTOR.
PI3Kα inhibitor 1
PI3Kα inhibitor 1 is an inhibitor of PI3Kα as well as HDAC and probably have antineoplastic activity. IC50: ＜0.1 μM.
CH5132799 is a novel class I PI3K inhibitor, which exhibited a strong inhibitory activity especially against PI3K; (IC(50)=0.014 uM). In human tumor cell lines ...
LY 294002 hydrochloride
LY 294002 hydrochloride is a PI 3-kinase inhibitor with IC50 values of 0.31μM for PI 3-Kβ, 0.73μM for PI 3-Kα, 1.06μM for PI 3-Kδ and 6.60μM for PI 3-Kγ. It can...
AM-9635 is a selective Phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor. AM-9635 exhibits good cellular potency (in vitro pAKT IC50 = 4.2 nM ). AM-9635 can...
This active molecular is a selective PI3Kδ inhibitor. PI3Kδ is hyperactivated in B-cell malignancies and plays a vital role in the B-cell receptor pathway. AM-0...
D 106669 is a potent and selective PI3K inhibitor.
AS-252424 is a novel, potent PI3Kγ inhibitor (IC50 of 30 nM) with a 30-fold selectivity for PI3Kγ than PI3Kα, and low inhibitory activity towards PI3Kδ/β.
GSK2269557, an effective PI3K inhibitor, could be used as against inflammatory and some autoimmune diseases. It has just completes a phase II trial against Asth...
This active molecular is the S-configuration isomer of AZD6482. AZD6482 is a selective, ATP competitive PI3Kβ inhibitor and IC50 value is 0.01 μm. Meanwhile, AZ...
NVP-QAV-572 is a potent PI3K kianse inhibitor.
CNX-1351 is a selective covalent Inhibitor of PI3Kα. In an end point assay, CNX-1351 potently inhibited PI3Kα and was 20−400 times less potent against β, γ, an...
3-Methyladenine is an autophagy inhibitor that protects cerebellar granule cells (CGCs) from apoptosis following serum/potassium deprivation. 3-Methyladenine in...
GDC-0077 is an orally available and selective PI3K inhibitor (IC50 = 0.038 + 0.003 nM) with > 300-fold selective over other Class I PI3K isoforms. GDC-0077 exer...
CZC24832 is the first selective inhibitor of phosphoinositide 3-kinase γ (PI3Kγ) with efficacy in in vitro and in vivo models of inflammation. Extensive target-...